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Many patients admitted to a hospital are already colonized with multi-drug resistant organ-
isms (MDRO) including third-generation cephalosporin-resistant Enterobacteriaceae
(3GCREB). The aim of our study was to determine the prevalence of rectal 3GCREB coloni-
zation at admission to a large German university hospital and to estimate infection inci-
dences. In addition, risk factors for 3GCREB colonization were identified.
Materials/Methods
In 2014 and 2015, patients were screened for rectal colonization with 3GCREB and filled out
a questionnaire on potential risk factors at admission to a non-intensive care unit (non-ICU).
All patients were retrospectively monitored for bacterial infections. Descriptive, univariable
and multivariable logistic regression analyses were conducted to identify risk factors for
3GCREB colonization at admission.
Results
Of 4,013 patients included, 10.3% (n = 415) were rectally colonized with 3GCREB at admis-
sion. Incidence of nosocomial infections was 3.5 (95% CI 2.0–6.1) per 100 patients rectally
colonized with 3GCREB compared to 2.3 (95% CI 1.8–3.0, P = 0.213) per 100 3GCREB
negative patients.
Independent risk factors for 3GCREB colonization were prior colonization / infection with
MDRO (OR 2.30, 95% CI 1.59–3.32), prior antimicrobial treatment (OR 1.97, 95% CI 1.59–
2.45), male sex (OR 1.38, 95% CI 1.12–1.70), prior travelling outside Europe (OR 2.39,
95% CI 1.77–3.22) and places of residence in the Berlin districts Charlottenburg-
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Wilmersdorf (OR 1.52, 95% CI 1.06–2.18), Friedrichshain-Kreuzberg (OR 2.32, 95% CI
1.44–3.74) and Mitte (OR 1.73, 95% CI 1.26–2.36).
Conclusions
Admission prevalence of rectal colonization with 3GCREB was high, while infection inci-
dence did not significantly differ between patients rectally colonized or not with 3GCREB at
hospital admission. In consequence, hospitals should prioritize improvement of standard
precautions including hand hygiene to prevent infections among all patients irrespective of
their 3GCREB status at hospital admission.
Introduction
The burden of third-generation cephalosporin-resistant Enterobacteriaceae (3GCREB) is
increasing worldwide [1–3]. Antimicrobial resistance is primarily facilitated by the production
of extended-spectrum beta lactamases (ESBL). Currently, about 7% of the population of Ger-
many is colonized with ESBL producing Enterobacteriaceae (ESBL-E) [4,5]. ESBL enzymes can
disrupt a large variety of beta-lactam antibiotics including third-generation cephalosporins
(3GC). Recently, Hamprecht et al. reported that 9.5% of patients admitted to German tertiary
care hospitals were colonized with 3GCREB [6]. Of those, ESBL production could be deter-
mined in more than 90% [6].
Risk factors for colonization with ESBL-E or 3GCREB can be either healthcare- or commu-
nity-associated. Known healthcare-associated risk factors are prior antimicrobial treatment,
previous hospitalization [4,6,7], a stay in a long-term care facility (LTCF), previous coloniza-
tion with multi-drug resistant organisms (MDRO) and medical treatment of gastroesophageal
reflux disease (GERD) [6].
One of the most important community-associated (CA) risk factors is travelling to high
prevalence regions including South-East Asia [4,7]. Nutritional habits, including meat con-
sumption (pork, chicken, beef), were described as probable sources of ESBL-E or ESBL-carry-
ing plasmids [8–11]. Thus far, regional or cultural risk factors for 3GCREB and ESBL-E
colonization remain poorly understood.
ESBL-E colonizing the human gut have the potential for causing infections [3]. The impact
of infections with ESBL-E is controversial. Some studies have reported an association of
ESBL-E infections with increased hospital costs, lengths of stay (LOS) and mortality [12,13],
while others have not [14,15]. However, inappropriate initial antibiotic treatment has been
shown to be more frequently in patients infected with ESBL-E [14,16]. Delayed initiation of
adequate antibiotic treatment may lead to increased morbidity and mortality, especially in vul-
nerable populations, e.g. intensive care unit (ICU) patients [17]. ESBL-E colonization is associ-
ated with infection incidence of 4% to 20% with respect to patient population, geography and
species analyzed [18–22].
The aim of our study was to analyze the prevalence of rectal 3GCREB colonization at
admission to a large German university hospital and to estimate the rate of infections among
those with and without rectal 3GCREB colonization. Infections among 3GCREB colonized
patients were analyzed in more detail. The secondary objective was to identify possible health-
care- and community-associated risk factors for 3GCREB colonization.
3GCREB admission prevalence and subsequent infection rates in a German hospital
PLOS ONE | https://doi.org/10.1371/journal.pone.0201548 August 1, 2018 2 / 17
the data privacy act. Interested researchers have
the opportunity to contact it-hygiene@charite.de to
get access to anonymized data, approved by the
data access committee at the “Institut fu¨r Hygiene
und Umweltmedizin, Charite´ Universita¨tsmedizin
Berlin”, we used for this analysis.
Funding: The admission screening was done as
part of the multi-center Antibiotic Therapy
Optimization Study (ATHOS) supported by the
German Center for Infection Research (DZIF). AMR
and MWP were supported by DZIF (grant number
TTU08.801, http://www.dzif.de). The funders had
no role in study design, data collection and
analysis, decision to publish, or preparation of the
manuscript.
Competing interests: The authors have declared
that no competing interests exist.
Materials and methods
Participants and setting
The study was conducted as part of the multi-center Antibiotic Therapy Optimization Study
(ATHOS) [6]. Our report is based on admission screenings at a German university hospital
with more than 3,000 beds.
Patients with an age of 18 years from general wards (anesthesiology, cardiology, dental
and oral medicine, gastroenterology, general surgery, gynecology, interdisciplinary unit,
hematology / oncology, nephrology, neurology, neurosurgery, orthopedics, radiation therapy,
transplant surgery, trauma surgery, urology, vascular surgery) were included in the study.
Excluded wards were intensive care units (ICUs), dermatology, obstetrics, ophthalmology,
otorhinolaryngology and psychiatry due to expected medical or personal probability to give
informed consent to participate in this study. ICU and wards of psychiatry have a high rate of
patients not being able to give informed consent for participation in a study, while patients of
dermatological, obstetrical, ophthalmological and otorhinolaryngological wards were expected
to have a low acceptance of a rectal admission screening. Patients were recruited between May
and September 2014 and between April and September 2015, respectively.
Enrolled patients were sampled for colonization with 3GCREB by rectal swabs within 3
days (day 1–3, day of admission = day 1) of admission. Rectal swabs were taken by the patient
or the healthcare staff. Each patient was asked to complete a questionnaire regarding potential
risk factors for colonization with MDRO including sex, age, current antibiotic treatment, ani-
mal contact and previous colonization with MDRO (methicillin-resistant Staphylococcus
aureus (MRSA), 3GCREB, carbapenem-resistant Enterobacteriaceae and vancomycin-resistant
enterococci (VRE)). In addition, it inquired about potential risk factors during the 6 months
prior to admission: previous antibiotic therapy, travel abroad, stay at rehabilitation center, stay
at a long-term care facility (LTCF), hospitalization (in Germany or abroad) and use of antacids
or proton-pump inhibitors for gastroesophageal reflux disease (GERD). The questionnaire
used in our study can be found in S1 File. In addition, the following information was extracted
from electronic patient files: place of residence (Berlin district), nationality classified by World
Health Organization (WHO) region [23], and ward of admission. For all patients, presence or
acquisition of an infection at admission or during the current hospital stay was analyzed.
Microbiological methods
Screening swabs (soaked with Amies transport medium) were taken from the rectum and cul-
tivated on ChromID ESBL agar (bioMe´rieux, Nu¨rtingen, Germany) selecting for ESBL-E. Spe-
cies identification and antibiotic susceptibility testing of bacteria grown on ChromID ESBL
agar was performed by Vitek 2 GN ID and AST N223 card (bioMe´rieux), respectively. Isolates
were included in the study, if they tested non-susceptible to cefotaxime, ceftriaxone or ceftazi-
dime using EUCAST breakpoints [24].
The combination disc test following EUCAST guidelines using cefotaxime, ceftazidime and
cefepime with and without clavulanate (Mast Diagnostica, Reinfeld, Germany) was performed
to confirm ESBL production [24].
Genotyping of 3GCREB isolates was conducted by repetitive-sequence-based PCR and sub-
sequent microfluidics electrophoresis using the DiversiLab system (bioMe´rieux).
Definition of infection
All patients were screened for the presence of bacteria in a clinical specimen (e.g. urine, blood,
wound). Electronic patient files of patients tested positive for bacteria in a clinical specimen
3GCREB admission prevalence and subsequent infection rates in a German hospital
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were examined in order to identify infections present at admission or acquired during the cur-
rent hospital stay.
Two independent infection control specialists searched patient files for evidence of bacterial
infections. A third infection control specialist was consulted in controversial cases. To qualify
an infection needed to meet the following criteria: 1) presence of bacteria in a clinical specimen
(e.g. urine, blood or wound) and 2) documentation of infection in patient file or appropriate
antimicrobial therapy instituted by treating physician. In case of several infections, the first
episode was counted.
Infections among patients colonized with 3GCREB were categorized as i) infection with
rectal 3GCREB or ii) infection with other bacteria (not rectal 3GCREB). Infection with rectal
3GCREB (i) was determined, if species identification and antibiotic susceptibility testing of
rectal and clinical isolates and / or strain-typing analysis were identical. Similarity of antibiotic
susceptibility testing was defined by variation of one two-fold dilution step of minimal
inhibitory concentration (MIC). Differences of more than one two-fold dilution step were
accepted for single substances, if this was most likely due to selection of resistance by antibiotic
exposure. When possible, additional strain typing analysis of rectal and clinical 3GCREB iso-
lates was conducted by repetitive-sequence-based PCR and subsequent microfluidics electro-
phoresis using the DiversiLab system (bioMe´rieux).
Community-acquired and nosocomial infections were monitored. All infections acquired
within 3 days (day 1–3, day of admission = day 1) of admission were defined as community-
acquired. Infections were considered nosocomial, if the patient had been admitted > 3 days
earlier than onset of infection.
Statistical analysis
The prevalence rate of 3GCREB at admission was defined as the number of patients positive
for 3GCREB per 100 patients screened. Infection incidence was defined as the number of
patients testing positive for infection per 100 patients with LOS> 3 days. Wilson score confi-
dence intervals of 3GCREB prevalence rates and infection incidences (infections / 100
patients) were calculated using Open Source Epidemiologic Statistics for Public Health, V3.01,
http://www.openepi.com [25].
In the descriptive analysis, numbers and percentages were calculated. Differences were
identified using the Chi-squared or Fisher’s exact test, respectively.
In the multivariable analysis, logistic regression models were applied to identify indepen-
dent risk factors for colonization with 3GCREB at admission. The following patient-based
parameters were considered in the analyses: age (45, 46–55, 56–65, 66–75 or > 75); sex
(male/ female); prior MDRO colonization; current antibiotic use, antibiotic use during the
previous 6 months; travel abroad during the previous 6 months inside or outside Europe; stay
at a rehabilitation centre or LTCF during the previous 6 months; hospital stay during the pre-
vious 6 months in Germany, in a European country outside Germany or outside Europe; occu-
pational or private animal contact; and treatment of GERD with antacids or proton-pump
inhibitors during the previous 6 months. Parameters were categorized as “no” (reference),
“yes” or “unknown”. Furthermore, the parameter ward of admission (cardiology, dental and
oral medicine, gastroenterology, general surgery, gynecology, hematology / oncology, interdis-
ciplinary unit, neurology, neurosurgery, orthopedics, radiation therapy, transplant surgery,
trauma surgery, vascular surgery, other) was included in the analyses. Due to low patient
counts, anesthesiology, urology and nephrology were merged into the category “other” wards.
The following parameters identified by the electronic patient files were included: place of
residence (not Berlin, Charlottenburg-Wilmersdorf, Friedrichshain-Kreuzberg, Lichtenberg,
3GCREB admission prevalence and subsequent infection rates in a German hospital
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Marzahn-Hellersdorf, Mitte, Neuko¨lln, Pankow, Reinickendorf, Steglitz-Zehlendorf, Spandau,
Tempelhof-Scho¨neberg, Treptow-Ko¨penick, unknown) and nationality classified by WHO
regions (African region, Region of Americas, South-East Asia Region, European Region, East-
ern Mediterranean Region and Western Pacific Region, unknown) [23]. The variables “wards
of admission”, “place of residence” and “region of origin” were dummy-coded. Reference cate-
gories for these variables were all other “wards of admission”, “places of residence” or “regions
of origin”, respectively.
In the multivariable analysis, the model building strategy was performed stepwise back-
ward, the significance level for excluding a parameter from the model was p = 0.05. For epide-
miological reasons, age and sex were included in all models. P values< 0.05 were considered
significant. All analyzes were performed using SPSS 22 (IBM SPSS Statistics, Somer, NY, USA)
and SAS 9.3 (SAS Institute, Cary, NC, USA).
Results
3GCREB colonization at admission to the hospital
Overall, 4,013 patients were included in this prevalence study. A flow diagram for study partic-
ipants is shown in Fig 1. Median age of the patients was 62 years (inter quartile range (IQR)
50–73), 50.3% (n = 2,019) were female. Charlson comorbidity index (CCI) was available for
97.1% (n = 3,900) of patients. Median CCI did not differ between all patients (CCI 3, IQR
1–5), 3GCREB negative patients (CCI 3, IQR 1–5) and 3GCREB colonized patients (CCI 3,
IQR 1–6). Prevalence of 3GCREB colonization at admission was 10.3% (415 of 4,013 patients,
95% CI 9.4–11.3%).
Fig 1. Flow diagram for study participants included in the 3GCREB prevalence study, Berlin, Germany, 2014/2015.
https://doi.org/10.1371/journal.pone.0201548.g001
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Microbiology of 3GCREB isolates
Fourteen patients (0.3%) were colonized with two different 3GCREB strains. Microbiological
analysis of 429 3GCREB isolates from 415 patients is summarized in Table 1. Of 429 Entero-
bacteriaceae isolated, 264 (61.5%) were resistant only to 3GC, 160 (37.3%) 3GCREB isolates
were also resistant to fluoroquinolones (FQ), and 5 isolates (1.2%) carried resistance to 3GC,
FQ and carbapenemes (C) simultaneously. The species most frequently identified among
3GCREB isolates were Escherichia (E.) coli (82.1%, 352 of 429 isolates), followed by Klebsiella
(K.) pneumoniae (7.9%, 34 isolates), Enterobacter spp. (5.6%, 24 isolates), Citrobacter spp.
(3.0%, 13 isolates), Klebsiella oxytoca (0.9%, four isolates) and Hafnia alvei (0.5%, two isolates).
Extended-spectrum beta-lactamase (ESBL) production was detected in 392 of 429 3GCREB
isolates (91.4%).
Infections
225 (5.6%) patients with infection were identified among 4,013 study participants. An over-
view of infections among all patients stratified by 3GCREB colonization status at hospital
admission can be found in Fig 2. Incidences of nosocomial infections were calculated for
patients with LOS > 3 days screened for colonization with 3GCREB at hospital admission
(Table 2). Median time until onset of nosocomial infection was 10.5 days (6–17 days) among
all patients, 9 days (IQR 6–18.5 days) among 3GCREB colonized patients and 10.5 days (6–16
days) among patients not colonized with 3GCREB at hospital admission.
Infections among 3GCREB negative patients. Infections diagnosed among 3GCREB
negative patients were infected wounds (n = 62, 30.9%), urinary tract infections (UTI, n = 55,
27.4%), bloodstream infections (BSI, n = 38, 18.9%), pneumonia (n = 18, 9.0%), intra-abdomi-
nal infections (n = 11, 5.5%), Clostridium difficile infections (CDI, n = 7, 3.5%), urosepsis
(n = 5, 2.5%), and others (n = 5, 2.5%). The latter included enteritis caused by Salmonella
infantis or Campylobacter jejuni, bacterial abscesses and an infected shoulder joint. One patient
was diagnosed with pneumonia and UTI at the same time. Pathogens identified most fre-
quently as causative agents of infections were: Escherichia coli (n = 55, 27.3%), Staphylococcus
Table 1. Distribution of resistances among 429 3GCREB isolates from 415 patients, 3GCREB prevalence study, Berlin, Germany, 2014/2015.










Total 429 (100%) 352 (82.1%) 34 (7.9%) 24 (5.6%) 13 (3.0%) 4 (0.9%) 2 (0.5%)
ESBL 392 (91.4%) 345 (80.4%) 34 (7.9%) 7 (1.6%) 3 (0.7%) 2 (0.5%) 1 (0.2%)
No ESBL 37 (8.6%) 7 (1.6%) 0 (0.0%) 17 (4.0%) 10 (2.3%) 2 (0.5%) 1 (0.2%)
Resistant to 3GC 264 (61.5%) 215 (61.1%) 14 (41.2%) 20 (83.3%) 11 (84.6%) 3 (75%) 1 (50%)
ESBL 234 (54.5%) 213 (60.5%) 14 (10.4%) 4 (16.7%) 1 (7.7%) 2 (50%) 0 (0.0%)
No ESBL 30 (7.0%) 2 (0.6%) 0 (0.0%) 16 (66.7%) 10 (76.9%) 1 (25%) 1 (50%)
Resistant to 3GC +
FQ
160 (37.3%) 135 (38.4%) 20 (58.9%) 3 (12.5%) 1 (1.7%) 0 (0.0%) 1 (50%)
ESBL 155 (36.1%) 131 (37.2%) 20 (58.9%) 2 (8.3%) 1 (1.7%) 0 (0.0%) 1 (50%)
No ESBL 5 (1.2%) 4 (1.4%) 0 (0.0%) 1 (4.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Resistant to 3GC +
FQ + C
5 (1.2%) 2 (0.6%) 0 (0.0%) 1 (4.2%) 1 (1.7%) 0 (0.0%) 0 (0.0%)
ESBL 3 (0.7%) 1 (0.3%) 0 (0.0%) 1 (4.2%) 1 (1.7%) 0 (0.0%) 0 (0.0%)
No ESBL 1 (0.2%) 1 (0.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
3GC—third generation cephalosporins, FQ—fluorquinolones, C—carbapenemes
https://doi.org/10.1371/journal.pone.0201548.t001
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aureus (n = 29, 14.4%), coagulase-negative staphylococci (n = 25, 12.4%), Enterococcus spp.
(n = 19, 9.5%) and Streptococcus spp. (n = 16, 8.0%).
Infections among 3GCREB colonized patients. Among the 415 3GCREB positive
patients, 25 (6.0%) had an infection at admission or developed an infection during the current
hospital stay. Six (1.4%) of 415 patients suffered from infections with the rectal 3GCREB and
21 (5.1%) with bacterial pathogens other than the rectal 3GCREB. Two of these patients (0.5%)
had an infection caused by 3GCREB and other pathogens simultaneously (Fig 2). Pathogens
other than 3GCREB detected most frequently in infected patients were E.coli susceptible to
3GC, Pseudomonas aeruginosa, Enterococcus faecalis, vancomycin resistant enterococci (VRE),
Staphylococcus aureus and Klebsiella pneumoniae susceptible to 3GC (S1 Table).
Fig 2. Overview of infections among study participants, 3GCREB prevalence study, Berlin, Germany, 2014/2015. CA—community-acquired, N—
nosocomial. Asterisks indicate that the clinical specimen of two patients colonized with 3GCREB were tested positive for 3GCREB and other pathogens
at the same time.
https://doi.org/10.1371/journal.pone.0201548.g002
Table 2. Infection incidences (with 95%CI) per 100 patients among 2,931 patients screened for 3GCREB coloniza-
tion at admission to the hospital and with LOS> 3 days. Patients stratified by positive (n = 316) or negative
3GCREB status (n = 2,615) at hospital admission, 3GCREB prevalence study, Berlin, Germany, 2014/2015.






All infections 2.3 (1.8–3.0) 3.5 (2.0–6.1) 0.213
Infections with rectal 3GCREB 1.3 (0.5–3.2)
Infections with other pathogens (not rectal
3GCREB)
2.9 (1.5–5.3)
95% CI—Confidence interval. P values were calculated by Chi-Squared test.
https://doi.org/10.1371/journal.pone.0201548.t002
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Of 25 patients with an incident infection, 11 patients (44.0%) acquired infection(s) during
the current hospital stay (> 3 days post admission), four of them with 3GCREB, nine with
other pathogens. Two of these patients acquired infections with 3GCREB and other pathogens
simultaneously (Fig 2). Median time until onset of nosocomial infection among 3GCREB colo-
nized patients was 6 days (IQR 4.75–10.5 days) for infections with rectal 3GCREB and 12 days
(IQR, 6.0–20.0 days) for infections with other pathogens.
The infection diagnosed most frequently among 3GCREB positive patients was urinary
tract infection (UTI, 12 of 25 patients; 48.0%), followed by bloodstream infections (BSI, 6 of 25
patients; 24.0%), intra-abdominal infections (6 of 25 patients, 24.0%) and one infected wound
(4.0%).
Of 352 patients colonized with 3GCR-E.coli, 4 (1.1%) developed an infection (two UTIs,
one intra-abdominal infection, one BSI) with 3GCR-E.coli. However, in 34 patients colonized
with 3GCR-Klebsiella pneumoniae, this agent accounted for one BSI and one intra-abdominal
infection (2 of 34 patients, 5.9%). This difference (1.0% versus 5.9%, P = 0.181) was not deter-
mined to be significant. Two of six 3GCREB colonized patients with subsequent 3GCREB
infection in this study were co-infected with VRE faecium (S1 Table).
Similarity of rectal and clinical isolates was tested by comparing the results of species identi-
fication and antibiotic susceptibility testing. Antimicrobial susceptibility of rectal isolates and
the respective clinical isolates were determined to be identical in six patients. In two of these
patients rectal isolates and the respective clinical specimen were available for strain-typing
analysis. This molecular analysis showed that the clinical specimen (urine, blood) of both
3GCREB infections tested were identical with the respective rectal isolate (S1 Fig). An over-
view of all 3GCREB positive patients with infections at admission or during the current hospi-
tal stay is shown in S1 Table.
Risk factor analysis for 3GCREB colonization
The complete descriptive analysis is presented in Table 3 and S2 Table. In brief, it shows that
3GCREB colonized patients were significantly more often male (56.9% versus 49.2%,
P = 0.003), took antibiotics at the time of admission (21.4% versus 15.5%, P = 0.002), and had
been previously colonized or infected with MDRO (10.1% versus 4.5%, P<0.001). Further-
more, patients more frequently tested positive for 3GCREB if—with respect to the previous 6
months—they had taken antibiotics (3.9% versus 2.9%, P<0.001), travelled outside Europe
(16.1% versus 7.5%, P<0.001), been admitted to a German hospital (38.3% versus 31.6%,
P = 0.012), stayed in LTCF (9.2% versus 8%, P = 0.024) or were being treated for GERD with
antacids or proton-pump inhibitors (43.6% versus 38.6%, P = 0.048). Patients colonized with
3GCREB at hospital admission lived significantly more often in Friedrichshain-Kreuzberg
(5.8% versus 2.7%, P< 0.001) and Mitte (13.7 versus 9.7, P = 0.010) and less frequently outside
Berlin (18.8 versus 24.3, P = 0.012). 3GCREB prevalence in Berlin stratified by district is
shown in Fig 3 [26].
Independent risk factors for 3GCREB colonization at hospital admission according to the
final multivariable model were prior MDRO colonization / infection (OR = 2.30, 95%
CI = 1.59–3.32), antimicrobial treatment (OR = 1.97, 95% CI = 1.59–2.45) and travelling out-
side Europe (OR = 2.39, 95% CI = 1.77–3.22) during the previous 6 months. Further risk fac-
tors were male sex (OR = 1.38, 95% CI = 1.12–1.70), places of residence in Charlottenburg-
Wilmersdorf (OR = 1.52, 95% CI = 1.06–2.18), Mitte (OR = 1.73, 95% CI = 1.26–2.36) and
Friedrichshain-Kreuzberg (OR = 2.32, 95% CI = 1.44–3.74). Protective factors associated with
a reduced risk of 3GCREB colonization were admission to a cardiology ward (OR = 0.73, 95%
3GCREB admission prevalence and subsequent infection rates in a German hospital
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Table 3. Descriptive ysis of demographic patient data of 4,013 patients screened for 3GCREB colonization at admission to the hospital. Patients stratified by positive
or negative 3GCREB status at admission, 3GCREB prevalence study, Berlin, Germany, 2014/anal 2015.
3GCREB status at admission Prevalence per 100 patients P-value
Parameter Category Negative Positive Positive
Patient 3598 (100%) 415 (100%) 10.3
Sex Male 1770 (49.2%) 236 (56.9%) 11.8 0.003
Age [years]  45 689 (19.1%) 83 (20.0%) 10.8 0.854
46–55 639 (17.8%) 65 (15.7%) 9.2
56–65 743 (20.7%) 84 (20.2%) 10.2
66–75 895 (24.9%) 107 (25.8%) 10.7
> 75 632 (17.6%) 76 (18.3%) 10.7
Ward of admission Cardiology 666 (18.5%) 62 (14.9%) 8.5 0.074
Dental and oral medicine 237 (6.6%) 31 (7.5%) 11.6 0.495
Gastroenterology 603 (16.8%) 80 (19.3%) 11.7 0.196
General surgery 81 (2.3%) 10 (2.4%) 11.0 0.837
Gynecology 104 (2.9%) 14 (3.4%) 11.9 0.581
Hematology/oncology 159 (4.4%) 27 (6.5%) 14.5 0.056
Interdisciplinary unit 71 (2%) 10 (2.4%) 12.3 0.550
Neurology 331 (9.2%) 32 (7.7%) 8.8 0.317
Neurosurgery 150 (4.2%) 18 (4.3%) 10.7 0.871
Orthopedics 309 (8.6%) 43 (10.4%) 12.2 0.227
Radiation therapy 37 (1%) 3 (0.7%) 7.5 0.553
Transplant surgery 35 (1%) 8 (1.9%) 18.6 0.074
Trauma surgery 599 (16.6%) 51 (12.3%) 7.8 0.022
Vascular surgery 211 (5.9%) 25 (6%) 10.6 0.896
Other 5 (0.1%) 1 (0.2%) 16.7 0.611
Place of residence (Berlin district) Charlottenburg-Wilmersdorf 257 (7.1%) 40 (9.6%) 13.5 0.066
Friedrichshain-Kreuzberg 98 (2.7%) 24 (5.8%) 19.7 0.001
Lichtenberg 81 (2.3%) 8 (1.9%) 9.0 0.672
Marzahn-Hellersdorf 86 (2.4%) 9 (2.2%) 9.5 0.779
Mitte 350 (9.7%) 57 (13.7%) 14.0 0.010
Neuko¨lln 176 (4.9%) 18 (4.3%) 9.3 0.618
NotBerlin 876 (24.3%) 78 (18.8%) 8.2 0.012
Pankow 159 (4.4%) 24 (5.8%) 13.1 0.207
Reinickendorf 216 (6%) 22 (5.3%) 9.2 0.566
Spandau 94 (2.6%) 12 (2.9%) 11.3 0.737
Steglitz-Zehlendorf 643 (17.9%) 67 (16.1%) 9.4 0.383
Tempelhof-Scho¨neberg 427 (11.9%) 47 (11.3%) 9.9 0.746
Treptow-Ko¨penick 125 (3.5%) 8 (1.9%) 6.0 0.096
Unknown 10 (0.3%) 1 (0.2%) 9.1 > 0.999
Region of origin African region 2 (0.1%) 0 (0.0%) 0.0
Eastern Mediterranean Region 9 (0.3%) 3 (0.7%) 25.0 0.095
European region 2458 (68.3%) 278 (67.0%) 10.2 0.582
Region of Americas 7 (0.2%) 0 (0.0%) 0.0
South-East Asian Region 1 (0.0%) 0 (0.0%) 0.0
Western Pacific region 2 (0.1%) 0 (0.0%) 0.0
Unknown 1119 (31.1%) 134 (32.3%) 10.7 0.621
P-values were calculated by Chi-Squared test or Fisher’s exact test, respectively.
P-values 0.05 were considered significant.
The parameters place of residence, ward of admission and region of origin were dummy-coded.
The category “Other” in ward of admission includes anesthesiology, nephrology and urology.
https://doi.org/10.1371/journal.pone.0201548.t003
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CI = 0.55–0.98) or a trauma surgery ward (OR = 0.67, 95% CI = 0.48–0.91). The multivariable
analysis is summarized in Table 4.
Discussion
Prevalence of 3GCREB colonization at hospital admission was high, while infection incidence
did not significantly differ between patients positive or negative for rectal colonization with
3GCREB at hospital admission. Further, we identified that community-associated risk factors
including travelling outside Europe and living in certain urban areas might play an important
role in 3GCREB colonization at hospital admission. In consequence, for non-ICU patients,
effectiveness of cost and labor intense measures including general admission screenings to pre-
vent transmission of 3GCREB colonization within the hospital may be questioned. Instead,
hospitals should focus on improvement of standard precautions including hand hygiene to
prevent infections among all patients irrespective of their 3GCREB colonization status at hos-
pital admission.
Fig 3. Comparison of Berlin district-dependent prevalence (in %) of rectal colonization with 3GCREB at admission to the hospital. Asterisks
indicate districts with significantly increased 3GCREB prevalence compared to other districts (multivariable logistic regression analysis). The map was
adjusted according to the geodata reference map published by a German newspaper [26]. 3GCREB prevalence study, Berlin, Germany, 2014/2015.
https://doi.org/10.1371/journal.pone.0201548.g003
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3GCREB colonization at admission to the hospital
The 3GCREB prevalence of 10.3% identified in this study is similar to recently published find-
ings demonstrating that 9.5% of patients were tested positive for 3GCREB at admission to Ger-
man hospitals [6]. Other studies investigating the prevalence of ESBL-E and ESBL-producing
E. coli in the population of Germany reported lower prevalence rates of 6 to 7% [4,5]. [1–3].
Hamprecht et al. and our study examined patients at admission to the hospital but not the gen-
eral population. The difference between these populations is illustrated by the high percentage
of patients included in our study reporting use of antibiotics during the previous six months
(>30%). This might explain the higher 3GCREB prevalence in patients admitted to the hospi-
tal. Furthermore, the range of 3GCREB prevalence in Germany varied between 5.1% and
11.8% depending on the hospital of admission [6]. Thus, regional differences are likely to have
an impact. Antibiotic resistance was facilitated by ESBL production in more than 90% of our
3GCREB isolates; more than 80% of those isolates were E. coli. This makes a comparison of
our data with studies investigating ESBL-E and ESBL-E. coli possible.
Infections
Interestingly, infection incidence among patients colonized with 3GCREB was not signifi-
cantly higher compared to patients not colonized with 3GCREB at hospital admission. In fact,
incidence of infections with the colonizing 3GCREB was very low among 3GCREB positive
patients at hospital admission. Carriers of ESBL-E were shown to have varying rates of subse-
quent infections depending on patient population, geography and the type of infection ana-
lyzed. A French hospital had ESBL-E infection incidence of 8% [19]. The rate differed between
4% and 20% among ESBL-E carriers in two French ICUs [20,22]. Furthermore, 8.5% of
ESBL-E colonized patients in American ICUs developed ESBL-E-BSI [21], while in an Israeli
hospital 15.4% of patients with fecal ceftazidime-resistant Enterobacteriaceae colonization had
a subsequent bacteremia with the same species [18]. The low incidence of infections with the
rectal 3GCREB among patients colonized with 3GCREB at hospital admission observed in the
present study might be explained by the fact that we focused on patients from general wards
and not high-risk patients. Below 5% of patients were admitted to a hematological / oncologi-
cal ward, while ICU patients were not considered in this analysis. Recently, high-risk patients
identified by a score-assigned prediction model were shown to have a significantly higher
cumulative probability of developing an infection with multi-drug resistant Gram-negative
bacteria (MDRGN) than lower risk patients [27].
Table 4. Results of the multivariable conditional logistic regression analysis of 4,013 patients to identify risk factors for colonization with 3GCREB at admission,
3GCREB prevalence study, Berlin, Germany, 2014/2015.
Parameter Category Odds Ratio 95% confidence interval P-value
Sex Male 1.38 1.12–1.70 0.003
Previous MDRO colonization / infection Yes 2.30 1.59–3.32 0.001
Antibiotic use during the previous 6 months Yes 1.97 1.59–2.45 0.005
Travelling to a non-European country during the previous 6 months Yes 2.39 1.77–3.22 0.028
Place of residence Charlottenburg-Wilmersdorf 1.52 1.06–2.18 0.024
Friedrichshain-Kreuzberg 2.32 1.44–3.74 0.001
Mitte 1.73 1.26–2.36 0.001
Ward of admission Cardiology 0.73 0.55–0.98 0.037
Trauma surgery 0.67 0.48–0.91 0.012
P-values 0.05 were considered significant.
https://doi.org/10.1371/journal.pone.0201548.t004
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The most frequent infections with the rectal 3GCREB were UTI, BSI and intra-abdominal
infections, reflecting the gastrointestinal and urinary tract as typical colonization sites of
ESBL-E [28]. Even though the majority of 3GCREB infections (all BSI, all intra-abdominal
infections) in our study were nosocomial, we also detected 3GCREB-UTIs not acquired during
the current hospital stay. Thus, infections with 3GCREB, especially UTI, are not restricted to
the hospital [29,30].
In this study, nosocomial infection was defined by onset of infection > 3 days post admis-
sion. Due to this strict definition, incidence of nosocomial infections might be underestimated.
However, we performed a sensitivity analysis. Infection incidences did not significantly differ,
if onset of infections 3 days post admission were considered nosocomial (2.5 infections per
100 patients with onset > 3 days post admission vs. 2.3 infections per 100 patients with
onset 3 days, P = 0.624).
Risk factors for 3GCREB colonization at hospital admission
Known health care-associated risk factors for ESBL-E colonization are antibiotic treatment
and prior colonization or infection with MDRO [6,31–36]. These risk factors were also
detected in our study. Moreover, as previously shown by others, male gender could be associ-
ated with 3GCREB colonization [18,30,35].
Multivariable analysis identified admission to trauma surgery and cardiology wards
as independent protective factors for 3GCREB colonization. This finding might be explained
by the facts that patients admitted to the ward of trauma surgery usually do not have a his-
tory of previous hospitalization and in most cases have fewer secondary diseases. Patients
admitted to the ward of cardiology usually have a lower rate of previous antibiotic
consumption.
In addition to healthcare-associated risk factors, the present study also focused on commu-
nity-associated risk factors for 3GCREB colonization. Travel outside Europe is reported as one
of the most important risk factors for ESBL-E colonization and was also identified by our
study [4,7]. In particular, contact with the Middle East / South Asia (MESA) has a significant
association with ESBL-E colonization [4,7,11,37]. The multivariable logistic regression analysis
identified residence in Friedrichshain-Kreuzberg, Mitte and Charlottenburg-Wilmersdorf as
independent risk factors for 3GCREB colonization at admission. We can only speculate as to
reasons for these regional differences. Interestingly, Friedrichshain-Kreuzberg, Mitte and
Charlottenburg-Wilmersdorf are the only Berlin districts without a border to Berlin’s city lim-
its. These three districts also have the highest residential and traffic densities per hectar [38].
Transmission might be more likely in urban areas with more frequent exposures to 3GCREB,
e.g. in households, apartment buildings, public transport, or supermarkets. A Spearman rank
order correlation found a strong correlation between 3GCREB prevalence and population
density (r = 0.62, P = 0.033) [38]. In contrast, no correlation was identified for households
of 4 person (r = 0.36, P = 0.245) or for foreigners from the Eastern Mediterranean region
(r = 0.22, P = 0.484) living in Berlin districts [38]. However, a causal relationship between
ESBL colonization and population density cannot be concluded from our data. ESBL transmis-
sion is complex and not yet fully understood, especially regarding community-associated risk
factors including cultural and nutritional habits [3]. Recently, living in Parisean area was iden-
tified with an elevated risk of ESBL-E colonization [39]. Certain urban areas might represent a
surrogate parameter for the complexity of risk factors for ESBL-E colonization. Such a combi-
nation of risk factors might include crowded housing conditions or frequent contact to high
prevalence areas, not only by nationality or travel, but also by having visitors or consuming
food from those areas. Having an Asian native language or a full name whose origin is in
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MESA were previously reported as further surrogate parameters for the complexity of ESBL
transmission [11,37].
Strengths and limitations
Our study has several limitations. First, this is a monocenter analysis done in a university hos-
pital. The ability to draw any general conclusions for other (tertiary care) hospitals is limited.
However, median CCI in our cohort is 3 (IQR 1–5), while median CCI among other non-ICU
patient cohorts in German university hospitals were reported to vary between 2 and 5.6
depending on underlying diseases [11,40,41]. In consequence, we expect our patient cohort to
be comparable to other non-ICU patients in German university hospitals.
Second, despite careful examination of infections among 3GCREB positive patients in elec-
tronic patient files independently by two infection control specialists, infections might have
been missed due to insufficient reporting by treating physicians or not taking enough cultures.
This would lead to an underestimation of infection incidence.
Third, similarity of rectal and clinical 3GCREB isolates was tested by comparing antibiotic
susceptibility testing and not by molecular analyses [42]. Unfortunately, rectal and clinical iso-
lates were available for only two of six 3GCREB colonized patients with 3GCREB infection.
However, similarity of rectal and clinical isolates could be verified by repetitive PCR-based
typing method in both cases. In consequence, our low 3GCREB infection rate might be
overestimated.
Fourth, two of six 3GCREB positive patients with subsequent 3GCREB infection were co-
infected with VRE faecium. The fact that patients are increasingly co-infected with more than
one multi-drug resistant organism including methicillin-resistant Staphyloccocus aureus
(MRSA), VRE, and ESBL-E has been shown previously [43]. Thus, the causing agent of these
infections cannot be clearly identified. In this study, those infections were counted as both,
3GCREB infections and infections with other pathogens. In consequence, this might lead to an
overestimation of 3GCREB infection rate. However, the overestimation of 3GCREB infection
rate does not change the conclusion of our study. Fifth, no discharge surveillance was done. If
patients were discharged before onset of infection, this infection was missed. Sixth, the defini-
tion of nosocomial infections in this study refers to the current hospital stay. We cannot
exclude that community-acquired infections might have been acquired during a previous stay
in the hospital or another healthcare institution.
Strengths of our study were the high number of patients included and the fact that our
study was done during the same season (May—September) on the same wards within two con-
secutive years (2014 and 2015). Further, this study included all species of 3GCREB and did not
focus on E.coli alone or excluded ESBL negative Enterobacteriaceae. We performed one of the
most extensive analyses of risk factors for colonization with 3GCREB including healthcare-
and community-associated parameters. To our knowledge, this is the first prevalence study
calculating infection incidences for non-ICU patients stratified by the 3GCREB colonization
status at hospital admission.
Outlook
The epidemiology of 3GCREB colonization is still not fully understood, especially in the field
of community-associated risk factors. Further studies including molecular analysis of
3GCREB isolates, e.g. by whole genome sequencing, are necessary to understand the epidemi-
ology and sources of these widespread multi-drug resistant Gram-negative organisms.
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